Answers are grounded in this paper and cite their sources.
In the early 1970s, when studies on borderline patients began in earnest, most inpatients received either an inadequate trial on any psychotropic drug or none at all. The literature of that period warned about the ineffectiveness¹,²or actual harmfulness³⁻⁷of pharmacologic treatment for borderline patients. A decade later, it had become rare for any inpatient with borderline personality disorder to be discharged without a vigorous trial of at least one psychotropic agent. Even in outpatient settings, the majority of patients had prior exposure to psychotropic medications.⁸This proliferation of drug treatments for borderline patients had taken place despite the absence of any controlled evaluations. In fact, the additions to the literature largely consisted of case series from which claims were made for the usefulness of monoamine oxidase inhibitors,⁹tricyclic antidepressants,¹⁰and low-dose phenothiazines.¹¹The greatly expanded awareness of the potential value of such pharmacotherapies
No takes yet. Share an insight, caveat, or question.
John G. Gunderson (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: